CompletedPhase 2NCT00771810
Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer
Studying Acquired neutropenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Tarix Pharmaceuticals
- Principal Investigator
- Gere S diZerega, MDUS Biotest, Inc.
- Intervention
- TXA127(drug)
- Enrollment
- 34 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2008 – 2011
Study locations (6)
- University of Southern Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
- USC - LAC Medical Center, Los Angeles, California, United States
- University of California - Irvine, Chao Family Comprehensive Cancer Center, Orange, California, United States
- Rush University Medical Center, Chicago, Illinois, United States
- Associates in Women's Health, Wichita, Kansas, United States
- Schwartz Gynecologic Oncology, PLLC, Brightwaters, New York, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00771810 on ClinicalTrials.govOther trials for Acquired neutropenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06056297A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious InfectionsX4 Pharmaceuticals
- RECRUITINGPHASE1, PHASE2NCT00967785A Phase I Study of Mozobil in the Treatment of Patients With WHIMSNational Institute of Allergy and Infectious Diseases (NIAID)